Meridian Bioscience, Inc. (VIVO)

FORT MILL, SC / ACCESSWIRE / October 21, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced a new publication in the October 2024 issue of HeartRhythm Case Reports. This recent publication focuses on a patient procedure in which a novel, non-invasive ablation technique known as stereotactic radioablation ("STAR") was used.

FORT MILL, SC / ACCESSWIRE / October 2, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a company dedicated in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced several updates for their VIVO non-invasive mapping system. Over the last 60 days and through the month of October the company has participated in several industry meetings where VIVO has been or will be highlighted.

FORT MILL, SC / ACCESSWIRE / September 5, 2024 / Catheter Precision, Inc. (NYSE American:VTAK) today announced that at the recently held European Society of Cardiology (ESC) Symposium, interim results demonstrating the use of VIVO in localizing the site of origin of ventricular tachycardia (VT) for patients with scar related re-entrant VT were presented. Additionally, the presentation showed the relationship to the relevant myocardial scar on cross-sectional imaging from the CT scan.

FORT MILL, SC / ACCESSWIRE / July 16, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that the patient follow-up phase for the VIVO European Registry has concluded. The EU registry began in October 2021 and patient enrollment concluded in June 2023.

FORT MILL, SC / ACCESSWIRE / June 20, 2024 / Catheter Precision, Inc. (the "Company") (NYSE American:VTAK), a US based innovative medical device company announced that it has received its first purchase order from Qatar. As previously announced, an initial evaluation of the VIVO product was completed earlier this year at Hamad Medical Corporation Heart Hospital in Doha.

- OCM™ was significantly better than comparators at halting proliferation of MRSA and PA –- OCM™ recorded the lowest bacterial counts of any treatment arm –- OCM™ showed significantly faster formation of new tissue in MRSA-infected wounds than any other treatment – SARASOTA, Fla., May 20, 2024 /PRNewswire/ -- Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, recently presented in vivo data showing that OCM™ wound matrix alone significantly reduced methicillin-resistant staphylococcus (MRSA) aureus and pseudomonas aeruginosa (PA) bacterial counts and accelerated the formation of new tissue in MRSA-infected wounds, outperforming a comparator treatment and a control group. Results of the in vivo data conducted in a porcine model—the most similar to human skin in both morphological structure and immunohistochemical properties1—were shown as a poster during the Symposium on Advanced Wound Care (SAWC) conference May 14 – 18. "Stalled wounds affect more than 6.5 million Americans, with devastating consequences for patients' physical, social, and mental health," said Suzanne Bakewell, Ph.D., Chief Scientific Officer at Omeza®. "Prolonged wound healing times significantly increase the risk of severe infection and resulting amputations, and thus they are a major challenge for healthcare professionals who treat them." "Limiting bacterial growth is a critical therapeutic aim in treating nonhealing wounds, but complicating factors often prevent success. OCM™ does not confer these complications, such as antibiotic resistance, cytotoxicity, or viral transmission, and we're excited by OCM™'s potential as a novel option for the management of stalled wounds." The current study was designed to evaluate the antimicrobial and wound-healing effects of OCM™ against a comparator and a control in a porcine wound model. OCM™ is a novel, propriety, drug/device comprising cold-water fish peptides and other pharmaceutical-grade ingredients that create an absorbable matrix which integrates into the wound bed to support the synthesis of new tissue. Study Design In the study, wounds were inoculated with MRSA and PA, then treated with either OCM™ alone and a silver dressing (positive control) or debridement only (negative control). Wounds in all groups were debrided, treated (except negative control), covered with polyurethane dressings, and retreated on days 4 and 8. All wounds were assessed on Days 4, 8, and 12 for bacterial counts, among other measures. Study Results Results of the study showed the following: "These in vivo data constitute an important finding that may have significant clinical implications for the management of many wound etiologies, such as burns, diabetic foot ulcers, venous leg ulcers, and pressure ulcers," said Dr. Windy Cole, DPM, adjunct professor and Director of Wound Care Research at Kent State University College of Podiatric Medicine. "In recent years, researchers have amassed compelling evidence of multiple pathways through which marine-derived ingredients exert their effects on the immune system and wound healing at both the cellular and molecular levels, including their ability to reduce inflammation and increase metabolic activity of fibroblasts and keratinocytes2-5, which are critical for protecting against microbial invasion," said Dr. Cole. "The in vivo study of OCM™ supports these foundational studies and demonstrates that a specific therapy—OCM™—confers these antimicrobial benefits in porcine wounds, and the potential is likely in human wounds, as well," Dr. Cole said. Omeza® is currently evaluating its platform in three clinical studies among patients with diabetic foot ulcers, venous leg ulcers, and chronic wounds of multiple wound etiologies in a real-world setting. Among the endpoints are safety; change in percent area reduction; ability to move wounds from chronicity to a healing trajectory in a 4-week period; and time to complete wound closure. References: 1https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547536/#:~:text=Porcine%20skin%20is%20often%20used,properties%20(15%E2%80%9318)2https://web.archive.org/web/20220425210925id_/https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.145063https://web.archive.org/web/20220425210925id_/https://onlinelibrary.wiley.com/doi/pdf/10.1111/exd.145064https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6117694/#B98-marinedrugs-16-002565https://www.hmpgloballearningnetwork.com/site/wmp/article/nutrition-411-omega-3-fatty-acids-and-wound-healing About OMEZA Omeza® is a commercial-stage regenerative skin and wound-care company that develops marine-based products comprising containing cold water fish peptides and other pharmaceutical-grade components designed to reduce inflammation, increase tissue proliferation, and support skin remodeling in adults with a range of chronic, non-healing wounds. Founded in 2014, the company currently markets OCM™ for the treatment of nonhealing wounds. OCM™ is also being evaluated in real-world settings and in multiple clinical trials to compare the effects of OCM™ versus standard of care on wound healing, pain reduction, quality of life, and other secondary endpoints in patients with diabetic ulcers, chronic venous leg ulcers, and multiple other wound types. The company is headquartered in Sarasota, Florida, and has manufacturing facilities located in Florida. Media Contacts:Bernadette Cupit[email protected]908-334-4554

After launching three new products and posting a second quarter of rising EPS growth, medical devices leader Merit Medical Systems is probing a new buy point. The post Medical Devices Stock Pumps Up Buy Point With New Innovations appeared first on Investor's Business Daily.

This quartet of stocks has plenty of growth ahead and is already profitable.

NEW YORK , Aug. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) 's  sale to Pfizer Inc. for $148.50 per share in cash.

NEW YORK , Aug. 8, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Meridian Bioscience, Inc. (NASDAQ: VIVO) 's  sale to SD Biosensor, Inc. and SJL Partners LLC for $34.00 per share in cash. If you are a Meridian shareholder, click here to learn more about your rights and options.

Meridian Bioscience (VIVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

VIVO stock is a hot topic on Wall Street today, not just because Meridian Biosciences released a fiscal update, but also due to takeover news. The post Meridian Biosciences (VIVO) Stock Trending on $1.5 Billion Buyout Agreement appeared first on InvestorPlace.

Meridian Bioscience Inc. VIVO, +7.02% announced an agreement Thursday to be acquired by a consortium of South Korea-based SD Biosensor Inc. 137310, +2.08% and private equity firm SJL Partners LLC in a cash deal valued at $1.53 billion. Under terms of the deal, Meridian shareholders will receive $34.00 in cash for each Meridian share they own, representing a 1.3% premium to Wednesday's closing price of $33.55.

100% technical buy signals. 8 new highs and up 15.79% in the last month.

Meridian Bioscience (VIVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CINCINNATI , May 23, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a leading global provider of diagnostic testing solutions and life science raw materials, announced today its participation in the 2022 H.C. Wainwright Global Investment Conference.